VERA News and Press, Vera Therapeutics Inc. From 01/03/23

Vera Therapeutics ( NASDAQ: VERA ) is down 65% in after-hours trading Tuesday after releasing top-line data from a phase 2 trial of atacicept in patients with immunoglobulin A nephropathy (IgAN). Although the candidate met its primary endpoint, investors may have been looking for ...

Atacicept met primary endpoint at 24 weeks, and also achieved statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline, with available data showing trend towards further reductions in proteinuria at week 36 Atacicept safety profile in IgAN...

Vera Therapeutics ( NASDAQ: VERA ) is poised to surge 35%-40% following the expected January 2023 release of phase 2 data on atacicept for IgA nephropathy (IgAN), according to Cowen. The firm has an outperform rating on the stock. Analyst Ritu Baral gives a 50-50 chance that ...

BRISBANE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s mana...

Dr. Barratt will discuss disease burden and pathogenesis of IgAN, a common cause of kidney failure and a high unmet medical need globally Event held Monday, November 28, 2022 at 2pm ET BRISBANE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VER...

Vera Therapeutics press release ( NASDAQ: VERA ): Q3 GAAP EPS of -$0.91 misses by $0.19 . Strong balance sheet with $114.4 million in cash, cash equivalents, and marketable securities as of September 30, 2022; together with $20.0 million drawn under credit facility in ...

Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy topline data planned to be presented in early Q1 2023 Initiated pivotal Phase 3 COMPASS clinical trial of atacicept in lupus nephritis Strong balance sheet with $114.4 million in cash, cash equivalents, and...

New analysis of Phase 2a JANUS clinical trial showed atacicept reduced immune complex levels in patients with IgA nephropathy (IgAN) Atacicept is the first therapeutic to show reduction in all of the three first hits of IgAN pathogenesis – serum galactose-deficient IgA1 (...

BRISBANE, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced two new abstracts featuring new clin...

BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s man...